Cagrilintide (10mg vials)
Price range: $335.00 through $1,050.00
For Research Use Only. Not for Use in diagnostic procedures.
This product is solely intended for research purposes as a chemical compound. Its designation permits its use exclusively for in vitro testing and laboratory experimentation. All information regarding this product provided on our website is purely educational. By law, any form of bodily introduction of this product into humans or animals is strictly prohibited. It should only be handled by professionals who are licensed and qualified. This product is neither a drug, food, nor cosmetic, and must not be misrepresented, misused, or mislabeled as such.
🔥 Exclusive Crypto Offer
Get an INSTANT 15% DISCOUNT when you pay with Bitcoin, Ethereum, Dogecoin, Bitcoin Cash, XRP, Solana, or USDT.
⚡ Don't have crypto? Buy it here in 5 minutes with easy guidance.
💡 Pro Tip: You can also pay with cryptocurrency using your verified Cash App or PayPal account for a fast and secure checkout!
Cagrilintide (10mg vials)
Swipe right to view full table →
Save over 70%!
Product Format |
10mg vials |
Vial Size |
10mg |
Vial Capacity |
3 mL |
Box Combinations |
50mg, 100mg, 150mg, 200mg |
Cost per milligram |
$5.25 – $6.70 |
- Peptide Partners Manufacturer ID: VI32
- Batch Id: CAG202603
- Peptide Partners Manufacturer ID: WF03
- Batch Id: CG202607
Research Studies
(for educational purposes only)
Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors
Authors: Jianjun Cao, Matthew J. Belousoff, Rachel M. Johnson, Peter Keov, Zamara Mariam, Giuseppe Deganutti, George Christopoulos, Caroline A. Hick, Steffen Reedtz-Runge, Tine Glendorf, Borja Ballarín-González, Kirsten Raun, Charles Bayly-Jones, Denise Wootten & Patrick M. Sexton
URL: https://www.nature.com/articles/s41467-025-58680-y
Scientific Summary
This study utilized cryogenic electron microscopy (cryo-EM) to elucidate the structural basis of cagrilintide’s interaction with amylin receptors (AMY1R, AMY2R, AMY3R) and the calcitonin receptor (CTR). The high-resolution structures revealed that cagrilintide adopts an amylin-like binding mode, characterized by a ‘bypass’ motif. However, specific amino acid substitutions and the N-terminal lipidation in cagrilintide induce distinct conformational dynamics in the receptor complexes compared to native amylin or other analogues. These unique structural features, particularly the way it engages with the receptors, are proposed to contribute to its potent and long-acting clinical efficacy as a dual agonist for weight management.
Plain English Summary
Scientists used powerful microscopes to take detailed pictures of how the drug cagrilintide works at a molecular level. They found that it attaches to special sensors on cells, called receptors, in a way that is similar to a natural hormone called amylin, which helps control appetite. However, cagrilintide has some unique features that make it interact with these receptors in a special way, causing a stronger and longer-lasting effect. This helps explain why cagrilintide is so effective at helping people lose weight.
Development of Cagrilintide, a Long-Acting Amylin Analogue
Authors: Thomas Kruse, Jakob Lerche Hansen, Kirsten Dahl, Lauge Schäffer, Ulrich Sensfuss, Christian Poulsen, Morten Schlein, Ann Maria Kruse Hansen, Claus Bekker Jeppesen, Charlotta Dornonville de la Cour, Trine Ryberg Clausen, Eva Johansson, Simone Fulle, Rikke Bjerring Skyggebjerg, Kirsten Raun
URL: https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00565
Scientific Summary
This paper details the medicinal chemistry efforts that led to the design and synthesis of cagrilintide, a long-acting amylin analogue for the treatment of obesity. Through a series of structure-activity relationship (SAR) studies, the authors optimized the peptide sequence and introduced a C20 fatty diacid via a γ-glutamic acid linker to the N-terminus. In vitro functional assays, including luciferase and cAMP assays, were performed on cell lines expressing human and rat amylin and calcitonin receptors. These experiments confirmed that cagrilintide is a potent dual agonist, activating both receptor types, which is crucial for its therapeutic effect on reducing food intake and body weight, as demonstrated in preclinical rat models.
Plain English Summary
This research paper describes how scientists designed and created the drug cagrilintide. They started with a natural hormone called amylin and made specific changes to its structure to make it more effective and last longer in the body. One key change was adding a fatty acid molecule, which helps the drug to be released slowly. They then tested the new drug in the lab on cells that have the same sensors as our own body. The results showed that cagrilintide is very good at activating these sensors, which in turn helps to control appetite and reduce body weight.
Does receptor balance matter? – Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models
Authors: A.T. Larsen, K.E. Mohamed, N. Sonne, E. Bredtoft, F. Andersen, M.A. Karsdal, K. Henriksen
URL: https://www.sciencedirect.com/science/article/pii/S0753332222012318
Scientific Summary
This study conducted a head-to-head comparison of two dual amylin and calcitonin receptor agonists (DACRAs), cagrilintide and KBP-336, to investigate the importance of their receptor activation balance. Using in vitro cell-based assays, the researchers found that while both peptides activated the amylin and calcitonin receptors, KBP-336 was more potent and showed a bias towards the calcitonin receptor compared to cagrilintide. Cagrilintide’s potency on both receptors was found to be similar to their natural ligands, confirming its role as a balanced dual agonist. These in vitro findings highlight that even within the same class of drugs, subtle differences in how they interact with their target receptors can exist, which may translate to different overall effects in the body.
Plain English Summary
In this study, scientists compared two similar drugs, cagrilintide and KBP-336, to see if there were any important differences in how they work. Both drugs are designed to activate two different sensors in the body that help control metabolism. In lab experiments, they found that both drugs did their job, but KBP-336 was more powerful and leaned more towards activating one of the sensors over the other. Cagrilintide, on the other hand, was more balanced in how it activated both sensors. This research shows that even very similar drugs can have slight differences in their actions, which could be important for how they affect the body.
Cagrilintide (10mg vials)
Swipe right to view full table →
Save over 70%!
Product Format |
10mg vials |
Vial Size |
10mg |
Vial Capacity |
3 mL |
Box Combinations |
50mg, 100mg, 150mg, 200mg |
Cost per milligram |
$5.25 – $6.70 |
- Peptide Partners Manufacturer ID: VI32
- Batch Id: CAG202603
- Peptide Partners Manufacturer ID: WF03
- Batch Id: CG202607
Research Studies
(for educational purposes only)
Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors
Authors: Jianjun Cao, Matthew J. Belousoff, Rachel M. Johnson, Peter Keov, Zamara Mariam, Giuseppe Deganutti, George Christopoulos, Caroline A. Hick, Steffen Reedtz-Runge, Tine Glendorf, Borja Ballarín-González, Kirsten Raun, Charles Bayly-Jones, Denise Wootten & Patrick M. Sexton
URL: https://www.nature.com/articles/s41467-025-58680-y
Scientific Summary
This study utilized cryogenic electron microscopy (cryo-EM) to elucidate the structural basis of cagrilintide’s interaction with amylin receptors (AMY1R, AMY2R, AMY3R) and the calcitonin receptor (CTR). The high-resolution structures revealed that cagrilintide adopts an amylin-like binding mode, characterized by a ‘bypass’ motif. However, specific amino acid substitutions and the N-terminal lipidation in cagrilintide induce distinct conformational dynamics in the receptor complexes compared to native amylin or other analogues. These unique structural features, particularly the way it engages with the receptors, are proposed to contribute to its potent and long-acting clinical efficacy as a dual agonist for weight management.
Plain English Summary
Scientists used powerful microscopes to take detailed pictures of how the drug cagrilintide works at a molecular level. They found that it attaches to special sensors on cells, called receptors, in a way that is similar to a natural hormone called amylin, which helps control appetite. However, cagrilintide has some unique features that make it interact with these receptors in a special way, causing a stronger and longer-lasting effect. This helps explain why cagrilintide is so effective at helping people lose weight.
Development of Cagrilintide, a Long-Acting Amylin Analogue
Authors: Thomas Kruse, Jakob Lerche Hansen, Kirsten Dahl, Lauge Schäffer, Ulrich Sensfuss, Christian Poulsen, Morten Schlein, Ann Maria Kruse Hansen, Claus Bekker Jeppesen, Charlotta Dornonville de la Cour, Trine Ryberg Clausen, Eva Johansson, Simone Fulle, Rikke Bjerring Skyggebjerg, Kirsten Raun
URL: https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00565
Scientific Summary
This paper details the medicinal chemistry efforts that led to the design and synthesis of cagrilintide, a long-acting amylin analogue for the treatment of obesity. Through a series of structure-activity relationship (SAR) studies, the authors optimized the peptide sequence and introduced a C20 fatty diacid via a γ-glutamic acid linker to the N-terminus. In vitro functional assays, including luciferase and cAMP assays, were performed on cell lines expressing human and rat amylin and calcitonin receptors. These experiments confirmed that cagrilintide is a potent dual agonist, activating both receptor types, which is crucial for its therapeutic effect on reducing food intake and body weight, as demonstrated in preclinical rat models.
Plain English Summary
This research paper describes how scientists designed and created the drug cagrilintide. They started with a natural hormone called amylin and made specific changes to its structure to make it more effective and last longer in the body. One key change was adding a fatty acid molecule, which helps the drug to be released slowly. They then tested the new drug in the lab on cells that have the same sensors as our own body. The results showed that cagrilintide is very good at activating these sensors, which in turn helps to control appetite and reduce body weight.
Does receptor balance matter? – Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models
Authors: A.T. Larsen, K.E. Mohamed, N. Sonne, E. Bredtoft, F. Andersen, M.A. Karsdal, K. Henriksen
URL: https://www.sciencedirect.com/science/article/pii/S0753332222012318
Scientific Summary
This study conducted a head-to-head comparison of two dual amylin and calcitonin receptor agonists (DACRAs), cagrilintide and KBP-336, to investigate the importance of their receptor activation balance. Using in vitro cell-based assays, the researchers found that while both peptides activated the amylin and calcitonin receptors, KBP-336 was more potent and showed a bias towards the calcitonin receptor compared to cagrilintide. Cagrilintide’s potency on both receptors was found to be similar to their natural ligands, confirming its role as a balanced dual agonist. These in vitro findings highlight that even within the same class of drugs, subtle differences in how they interact with their target receptors can exist, which may translate to different overall effects in the body.
Plain English Summary
In this study, scientists compared two similar drugs, cagrilintide and KBP-336, to see if there were any important differences in how they work. Both drugs are designed to activate two different sensors in the body that help control metabolism. In lab experiments, they found that both drugs did their job, but KBP-336 was more powerful and leaned more towards activating one of the sensors over the other. Cagrilintide, on the other hand, was more balanced in how it activated both sensors. This research shows that even very similar drugs can have slight differences in their actions, which could be important for how they affect the body.
Third-party testing
Peptide Partners is committed to providing high-purity peptides at wholesale prices by frequently auditing its manufacturing partners using third-party laboratories. Independent analysis is vital to ensuring the quality and authenticity of your research peptides. Never trust a supplier that doesn’t submit to third-party testing. Never trust a certification that cannot be independently verified. All of the certificates that we provide can be validated on the third-party laboratory’s website.
Each product description contains a Manufacturer ID corresponding to the producer of that product. The table below contains the most recent third-party analyses for all manufacturers and peptides listed on Peptide Partners.
Current Purity certifications
Swipe right to view full table →
| Peptide | Batch Id | Manufacturer | Date | Purity | Laboratory | Double Validated | |
|---|---|---|---|---|---|---|---|
| Kisspeptin-10 | KSS2607 | VI32 | 2026-07-02 | 99.71% | Kovera | View File | |
| Reconstitution Solution | BAC202606 | WF03 | 2026-07-13 | 99.9% | Kovera | View File | |
| Retatrutide | RTT2613 | WF03 | 2026-07-02 | 99.77% | Kovera | View File | |
| PT-141 | PT202605 | VI32 | 2026-06-25 | 99.74% | Kovera | View File | |
| Tesamorelin | TES202607 | WF03 | 2026-06-19 | 99.80% | TrustPointe | View File | |
| KPV | KV202606 | WF03 | 2026-06-12 | 99.36% | TrustPointe | Yes | View File |
| BPC-157 | BC202607 | WF03 | 2026-06-12 | 99.82% | TrustPointe | Yes | View File |
| Ipamorelin | IP202606 | WF03 | 2026-06-12 | 99.98% | TrustPointe | Yes | View File |
| Semaglutide | SM202607 | VI32 | 2026-06-12 | 99.96% | TrustPointe | Yes | View File |
| Retatrutide | RTT202606 | WF03 | 2026-06-12 | 99.36% | Kovera | Yes | View File |
| CJC-1295 ND | CJ202606 | WF03 | 2026-06-10 | 99.88% | TrustPointe | Yes | View File |
| BPC-157 | BC202607 | WF03 | 2026-06-10 | 99.74% | Kovera | Yes | View File |
| Ipamorelin | IP202606 | WF03 | 2026-06-10 | 99.71% | Kovera | Yes | View File |
| Retatrutide | RT202607 | WF03 | 2026-06-09 | 99.76% | Kovera | View File | |
| Tirzepatide | TZ202605 | WF03 | 2026-06-09 | 99.55% | Kovera | Yes | View File |
| Semaglutide | SM202607 | VI32 | 2026-06-10 | 99.68% | Kovera | Yes | View File |
| KPV | KV202606 | WF03 | 2026-06-10 | 99.70% | Kovera | Yes | View File |
| Tirzepatide | TZ202605 | WF03 | 2026-06-10 | 99.34% | TrustPointe | Yes | View File |
| CJC-1295 ND | CJ202606 | WF03 | 2026-06-09 | 99.65% | Kovera | Yes | View File |
| Reconstitution Solution | BAC202603 | VI32 | 2026-06-09 | 99.90% | Kovera | Yes | View File |
| NAD+ | NDB202606 | WF03 | 2026-05-28 | 99.55% | TrustPointe | View File | |
| GHK-Cu | CU202605 | WF03 | 2026-05-13 | 99.67% | TrustPointe | View File | |
| Epithalon | ET202604 | WF03 | 2026-05-13 | 99.86% | Kovera | View File | |
| 5-Amino-1MQ | AM202604 | WF03 | 2026-05-13 | 99.78% | Kovera | Yes | View File |
| 5-Amino-1MQ | AM202604 | WF03 | 2026-05-29 | 99.53% | Chromate | Yes | View File |
| Reconstitution Solution | BAC202603 | VI32 | 2026-06-11 | 99.22% | TrustPointe | Yes | View File |
| MOTS-c | MC202605 | WF03 | 2026-06-08 | 99.98% | TrustPointe | View File | |
| Retatrutide | RTT202606 | WF03 | 2026-06-08 | 99.94% | TrustPointe | Yes | View File |
| TB-500 (TB4) | TB202605 | WF03 | 2026-05-28 | 99.76% | TrustPointe | View File | |
| Tesamorelin | TES202605 | WF03 | 2026-05-28 | 99.81% | TrustPointe | View File | |
| Retatrutide | RT202605 | WF03 | 2026-05-27 | 99.75% | TrustPointe | View File | |
| Reconstitution Solution | BAC202602 | VI32 | 2026-05-14 | 99.90% | Kovera | View File | |
| CJC-1295 ND / Ipamorelin | CJIP202605 | WF03 | 2026-05-14 | 99.93% | TrustPointe | View File | |
| Cagrilintide | CG202607 | WF03 | 2026-05-14 | 99.74% | TrustPointe | View File | |
| BPC-157/TB-500 | BB202605 | VI32 | 2026-05-14 | 99.73% | TrustPointe | Yes | View File |
| GHK-Cu | CU202604 | WF03 | 2026-05-14 | 99.74% | TrustPointe | Yes | View File |
| BPC-157 | BC202604 | VI32 | 2026-05-13 | 99.72% | TrustPointe | Yes | View File |
| CIT: CJC-1295 ND / Ipamorelin / Tesamorelin | CIT202604 | WF03 | 2026-05-07 | 99.82% | Kovera | View File | |
| Tesamorelin | TES202604 | WF03 | 2026-04-21 | 99.85% | Kovera | View File | |
| DSIP | DS202605 | WF03 | 2026-05-07 | 99.81% | Kovera | View File | |
| BPC-157/TB-500 | BB202605 | VI32 | 2026-04-21 | 99.90% | Kovera | Yes | View File |
| KLOW Blend | KW202604 | WF03 | 2026-04-21 | 99.86% | Kovera | View File | |
| AOD-9604 | AO202605 | WF03 | 2026-04-20 | 99.93% | Kovera | View File | |
| Cagrilintide | CG202603 | VI32 | 2026-04-14 | 99.90% | Kovera | View File | |
| MOTS-c | MC202603 | VI32 | 2026-04-04 | 99.96% | Kovera | View File | |
| Retatrutide | RT202604 | WF03 | 2026-04-16 | 99.54% | TrustPointe | View File | |
| Sermorelin | SER202601 | VI32 | 2026-04-01 | 99.94% | Kovera | View File | |
| Pinealon | PN202603 | WF03 | 2026-04-01 | 99.96% | Kovera | View File | |
| GHK-Cu | CU202604 | WF03 | 2026-04-03 | 99.93% | Kovera | Yes | View File |
| SS-31 | SS202601 | WF03 | 2026-04-03 | 99.82% | TrustPointe | View File | |
| Semax | SX202603 | WF03 | 2026-03-31 | 99.91% | Kovera | View File | |
| Retatrutide | RT202603 | WF03 | 2026-03-30 | 99.40% | TrustPointe | View File | |
| GLOW Blend | GW202603 | WF03 | 2026-03-25 | 99.88% | Kovera | View File | |
| Tirzepatide | TZ202603 | VI32 | 2026-03-27 | 99.89% | TrustPointe | View File | |
| BPC-157/TB-500 | BB202604 | WF03 | 2026-03-27 | 99.63% | TrustPointe | View File | |
| Tesamorelin | TES202603 | WF03 | 2026-03-25 | 99.52% | TrustPointe | View File | |
| BPC-157 | BC202604 | VI32 | 2026-03-18 | 99.60% | TrustPointe | Yes | View File |
| Ipamorelin/CJC-1295 (No DAC) | CJIP202602 | WF03 | 2026-02-27 | 99.92% | TrustPointe | View File | |
| Thymosin Alpha-1 | TA202602 | WF03 | 2026-02-25 | 99.95% | Kovera | View File | |
| KLOW | KW202602 | WF03 | 2026-03-01 | 99.86% | Chromate | View File | |
| NAD+ | NDB202601 | VI32 | 2026-02-07 | 99.92% | Kovera | View File | |
| SS-31 | SS202602 | WF03 | 2026-02-08 | 99.68% | Chromate | View File | |
| MOTS-c | MC202602 | WF03 | 2026-02-09 | 99.41% | Chromate | View File | |
| Selank | SEK202601 | VI32 | 2026-01-29 | 99.94% | Chromate | View File | |
| Unbuffered NAD+ | NDU202601 | MZ21 | 2026-01-20 | 99.85% | Chromate | View File | |
| KPV | KV202601 | VI32 | 2026-01-20 | 99.90% | Chromate | View File | |
| Ipamorelin | IP202601 | WF03 | 2026-01-14 | 99.92% | TrustPointe | View File | |
| TB500 (TB4) | TB202601 | WF03 | 2026-01-14 | 99.86% | TrustPointe | View File | |
| Retatrutide | RT202602 | WF03 | 2026-01-13 | 99.63% | TrustPointe | View File | |
| PT-141 | PT202512 | VI32 | 2026-01-12 | 99.89% | BioRegen | View File | |
| Semaglutide | SM202601 | MZ21 | 2026-01-10 | 99.70% | TrustPointe | View File | |
| Cagrilintide | CAG202601 | MZ21 | 2026-01-10 | 99.33% | TrustPointe | View File | |
| Tesamorelin | TES202601 | WF03 | 2025-12-29 | 99.71% | TrustPointe | View File | |
| BPC-157 | BP202512 | WF03 | 2025-12-29 | 99.46% | TrustPointe | View File | |
| BPC-157/TB-500 | BB202512 | WF03 | 2025-12-29 | 99.64% | TrustPointe | View File | |
| GHK-Cu | GK202512 | SH07 | 2025-12-19 | 99.79% | BioRegen | View File | |
| MOTS-c | MC202512 | WF03 | 2025-12-22 | 99.89% | BioRegen | View File | |
| Retatrutide | RP260130 | VI32 | 2025-12-22 | 99.72% | TrustPointe | View File | |
| SS-31 | SS202512 | WF03 | 2025-12-19 | 99.70% | TrustPointe | View File | |
| Retatrutide | RP202601 | DF05 | 2025-12-22 | 99.63% | TrustPointe | View File | |
| Ipamorelin/CJC-1295 (No DAC) | CJIP202512 | WF03 | 2025-12-09 | 99.80% | TrustPointe | View File | |
| Retatrutide | RP202511 | DF05 | 2025-12-19 | 99.73% | TrustPointe | View File | |
| Retatrutide | RP20251020 | DF05 | 2025-11-10 | 99.33% | TrustPointe | View File | |
| Retatrutide | RP20251001 | DF05 | 2025-10-13 | 99.86% | TrustPointe | View File | |
| Tirzepatide | TZ20250915 | DF05 | 2025-10-03 | 99.74% | TrustPointe | View File | |
| Retatrutide | RP20250929 | VI32 | 2025-10-03 | 99.47% | TrustPointe | View File | |
| Humanin | HP20250805 | WF03 | 2025-09-19 | 99.92% | BioRegen | View File | |
| MOTS-c | YC20250807 | WF03 | 2025-09-19 | 99.87% | BioRegen | View File | |
| DSIP | DS20250820 | SH07 | 2025-09-19 | 99.88% | BioRegen | View File | |
| SS-31 | SY20250806 | WF03 | 2025-09-19 | 99.70% | BioRegen | View File | |
| CJC/Ipamorelin | CI20250805 | WF03 | 2025-09-11 | 99.84% | TrustPointe | View File | |
| BPC-157 | BP20250808 | WF03 | 2025-09-05 | 99.99% | TrustPointe | View File | |
| Sermorelin | SM20250723 | WF03 | 2025-08-27 | 99.84% | BioRegen | View File | |
| Tesamorelin | TS20250722 | WF03 | 2025-08-22 | 99.10% | TrustPointe | View File | |
| CJC-1295 ND | CJ20250724 | WF03 | 2025-08-20 | 99.43% | TrustPointe | View File | |
| Semaglutide | SM20250801 | EJ12 | 2025-08-20 | 99.34% | TrustPointe | View File | |
| Ipamorelin | IP20250721 | WF03 | 2025-08-15 | 99.64% | TrustPointe | View File | |
| GHK-Cu | CU20250717 | SH07 | 2025-08-09 | 99.73% | BioRegen | View File | |
| Tirzepatide | TZ20250730 | EJ12 | 2025-08-08 | 99.41% | TrustPointe | View File | |
| NAD+ | ND20250503 | SH07 | 2025-07-31 | 99.76% | BioRegen | View File | |
| VIP | VP20250511 | SH07 | 2025-07-31 | 99.42% | BioRegen | View File | |
| Retatrutide | CD20250708 | SH07 | 2025-07-25 | 99.42% | TrustPointe | View File | |
| BPC/TB500 | BB20250630 | SH07 | 2025-07-17 | 99.52% | TrustPointe | View File | |
| TB500 (TB4) | TB20250614 | SH07 | 2025-07-17 | 99.68% | TrustPointe | View File |
Current Endotoxin Certifications
Swipe right to view full table →
| Peptide | Batch Id | Manufacturer | Date | USP Conformation | Laboratory | |
|---|---|---|---|---|---|---|
| Kisspeptin-10 | KSS2607 | VI32 | 2026-06-30 | Conforms | Kovera | View File |
| Reconstitution Solution | BAC202606 | WF03 | 2026-07-13 | Conforms | Kovera | View File |
| Retatrutide | RTT2613 | WF03 | 2026-06-30 | Conforms | Kovera | View File |
| Tesamorelin | TES202607 | WF03 | 2026-06-22 | Conforms | TrustPointe | View File |
| CJC-1295 ND | CJ202606 | WF03 | 2026-06-15 | Conforms | TrustPointe | View File |
| PT-141 | PT202605 | VI32 | 2026-06-12 | Conforms | Kovera | View File |
| Retatrutide | RTT202606 | WF03 | 2026-06-12 | Conforms | Kovera | View File |
| MOTS-c | MC202605 | WF03 | 2026-06-11 | Conforms | TrustPointe | View File |
| Semaglutide | SM202607 | VI32 | 2026-06-10 | Conforms | Kovera | View File |
| Ipamorelin | IP202606 | WF03 | 2026-06-10 | Conforms | Kovera | View File |
| KPV | KV202606 | WF03 | 2026-06-10 | Conforms | Kovera | View File |
| BPC-157 | BC202607 | WF03 | 2026-06-10 | Conforms | Kovera | View File |
| Retatrutide | RT202607 | WF03 | 2026-06-09 | Conforms | Kovera | View File |
| Tirzepatide | TZ202605 | WF03 | 2026-06-09 | Conforms | Kovera | View File |
| Reconstitution Solution | BAC202603 | VI32 | 2026-06-09 | Conforms | Kovera | View File |
| Reconstitution Solution | BAC202603 | VI32 | 2026-06-11 | Conforms | TrustPointe | View File |
| Epithalon | ET202604 | WF03 | 2026-05-13 | Conforms | Kovera | View File |
| 5-Amino-1MQ | AM202604 | WF03 | 2026-05-13 | Conforms | Kovera | View File |
| NAD+ | NDB202606 | WF03 | 2026-05-28 | Conforms | TrustPointe | View File |
| TB-500 (TB4) | TB202605 | WF03 | 2026-05-28 | Conforms | TrustPointe | View File |
| Tesamorelin | TES202605 | WF03 | 2026-05-28 | Conforms | TrustPointe | View File |
| Retatrutide | RT202605 | WF03 | 2026-05-27 | Conforms | TrustPointe | View File |
| CJC-1295 ND / Ipamorelin | CJIP202605 | WF03 | 2026-05-14 | Conforms | TrustPointe | View File |
| GHK-Cu | CU202605 | WF03 | 2026-05-18 | Conforms | TrustPointe | View File |
| Cagrilintide | CG202607 | WF03 | 2026-05-18 | Conforms | TrustPointe | View File |
| CIT: CJC-1295 ND / Ipamorelin / Tesamorelin | CIT202604 | WF03 | 2026-05-07 | Conforms | Kovera | View File |
| Tesamorelin | TES202604 | WF03 | 2026-04-21 | Conforms | Kovera | View File |
| DSIP | DS202605 | WF03 | 2026-05-07 | Conforms | Kovera | View File |
| BPC-157/TB-500 | BB202605 | VI32 | 2026-04-21 | Conforms | Kovera | View File |
| KLOW Blend | KW202604 | WF03 | 2026-04-21 | Conforms | Kovera | View File |
| AOD-9604 | AO202605 | WF03 | 2026-04-20 | Conforms | Kovera | View File |
| Retatrutide | RT202604 | WF03 | 2026-04-16 | Conforms | TrustPointe | View File |
| MOTS-c | MC202603 | VI32 | 2026-04-04 | Conforms | Kovera | View File |
| Pinealon | PN202603 | WF03 | 2026-04-01 | Conforms | Kovera | View File |
| Cagrilintide | CG202603 | VI32 | 2026-04-14 | Conforms | Kovera | View File |
| Sermorelin | SER202601 | VI32 | 2026-04-01 | Conforms | Kovera | View File |
| GHK-Cu | CU202604 | WF03 | 2026-04-03 | Conforms | Kovera | View File |
| SS-31 | SS202601 | WF03 | 2026-04-03 | Conforms | TrustPointe | View File |
| Semax | SX202603 | WF03 | 2026-03-31 | Conforms | Kovera | View File |
| Retatrutide | RT202603 | WF03 | 2026-03-30 | Conforms | TrustPointe | View File |
| GLOW Blend | GW202603 | WF03 | 2026-03-25 | Conforms | Kovera | View File |
| Tirzepatide | TZ202603 | VI32 | 2026-03-27 | Conforms | TrustPointe | View File |
| BPC-157/TB-500 | BB202604 | WF03 | 2026-03-26 | Conforms | TrustPointe | View File |
| Tesamorelin | TES202603 | WF03 | 2026-03-25 | Conforms | TrustPointe | View File |
| SS-31 | SS202602 | WF03 | 2026-02-25 | Conforms | Kovera | View File |
| CJC-1295 ND/Ipamorelin | CJIP202602 | WF03 | 2026-02-25 | Conforms | Kovera | View File |
| KLOW Blend | KW202602 | WF03 | 2026-02-25 | Conforms | Kovera | View File |
| BPC-157 | BC202604 | WF03 | 2026-03-17 | Conforms | Kovera | View File |
| Thymosin Alpha-1 | TA202601 | WF03 | 2026-02-25 | Conforms | Kovera | View File |
| MOTS-c | MC202602 | WF03 | 2026-02-08 | Conforms | Kovera | View File |
| NAD+ | NDB202601 | VI32 | 2026-02-08 | Conforms | Kovera | View File |
| Unbuffered NAD+ | NDU202601 | MZ21 | 2026-01-28 | Conforms | TrustPointe | View File |
| KPV | KV202601 | VI32 | 2026-01-28 | Conforms | TrustPointe | View File |
| Ipamorelin | IP202601 | WF03 | 2026-01-13 | Conforms | TrustPointe | View File |
| TB500 | TB202601 | WF03 | 2026-01-13 | Conforms | TrustPointe | View File |
| Retatrutide | RT202602 | WF03 | 2026-01-13 | Conforms | TrustPointe | View File |
| PT-141 | PT202512 | VI32 | 2026-01-07 | Conforms | BioRegen | View File |
| Semaglutide | SM202601 | MZ21 | 2026-01-10 | Conforms | TrustPointe | View File |
| Cagrilintide | CAG202601 | MZ21 | 2026-01-10 | Conforms | TrustPointe | View File |
| Tesamorelin | TES202601 | WF03 | 2026-01-06 | Conforms | TrustPointe | View File |
| BPC-157 | BP202512 | WF03 | 2025-12-30 | Conforms | TrustPointe | View File |
| BPC-157/TB-500 | BB202512 | WF03 | 2025-12-30 | Conforms | TrustPointe | View File |
| Retatrutide | RP260130 | DF05 | 2025-12-22 | Conforms | TrustPointe | View File |
| SS-31 | SS202512 | WF03 | 2025-12-19 | Conforms | TrustPointe | View File |
| Retatrutide | RP202601 | DF05 | 2025-12-22 | Conforms | TrustPointe | View File |
| Ipamorelin/CJC-1295 (No DAC) | CJIP202512 | WF03 | 2025-12-08 | Conforms | TrustPointe | View File |
| Retatrutide | RP202511 | DF05 | 2025-11-10 | Conforms | TrustPointe | View File |
| Retatrutide | RP20251020 | DF05 | 2025-11-10 | Conforms | TrustPointe | View File |
| Retatrutide | RP20251001 | DF05 | 2025-10-13 | Conforms | TrustPointe | View File |
| Tirzepatide | TZ20250915 | DF05 | 2025-10-03 | Conforms | TrustPointe | View File |
| Retatrutide | RP20250929 | VI32 | 2025-10-03 | Conforms | TrustPointe | View File |
| Humanin | HP20250805 | WF03 | 2025-09-19 | Conforms | BioRegen | View File |
| MOTS-c | YC20250807 | WF03 | 2025-09-19 | Conforms | BioRegen | View File |
| DSIP | DS20250820 | SH07 | 2025-09-19 | Conforms | BioRegen | View File |
| SS-31 | SY20250806 | WF03 | 2025-09-19 | Conforms | BioRegen | View File |
| CJC/Ipamorelin | CI20250805 | WF03 | 2025-09-03 | Conforms | TrustPointe | View File |
| BPC-157 | BP20250808 | WF03 | 2025-09-03 | Conforms | TrustPointe | View File |
| Bacteriostatic Water | BAC20250807 | SH07 | 2025-08-27 | Conforms | BioRegen | View File |
| Tesamorelin | TS20250722 | WF03 | 2025-08-20 | Conforms | TrustPointe | View File |
| CJC-1295 ND | CJ20250724 | WF03 | 2025-08-20 | Conforms | TrustPointe | View File |
| Sermorelin | SM20250723 | WF03 | 2025-08-20 | Conforms | TrustPointe | View File |
| Semaglutide | SM20250801 | EJ12 | 2025-08-20 | Conforms | TrustPointe | View File |
| Ipamorelin | IP20250721 | WF03 | 2025-08-11 | Conforms | TrustPointe | View File |
| GHK-Cu | CU20250717 | SH07 | 2025-08-08 | Conforms | TrustPointe | View File |
| Tirzepatide | TZ20250730 | EJ12 | 2025-08-04 | Conforms | TrustPointe | View File |
| NAD+ | ND20250503 | SH07 | 2025-07-29 | Conforms | TrustPointe | View File |
| VIP | VP20250511 | SH07 | 2025-07-29 | Conforms | TrustPointe | View File |
| Retatrutide | CD20250708 | SH07 | 2025-07-24 | Conforms | TrustPointe | View File |
| BPC/TB500 | BB20250630 | SH07 | 2025-07-17 | Conforms | TrustPointe | View File |
| TB500 (TB4) | TB20250614 | SH07 | 2025-07-17 | Conforms | TrustPointe | View File |
Current Heavy Metal Certifications
Swipe right to view full table →
| Peptide | Batch Id | Manufacturer | Date | Class 1 USP | Full USP | Laboratory |
|---|---|---|---|---|---|---|
| Kisspeptin-10 | KSS2607 | VI32 | 2026-07-01 | Conforms | Kovera | View File |
| Retatrutide | RTT2613 | WF03 | 2026-07-01 | Conforms | Kovera | View File |
| Ipamorelin | IP202606 | WF03 | 2026-06-26 | Conforms | TrustPointe | View File |
| KPV | KV202606 | WF03 | 2026-06-26 | Conforms | TrustPointe | View File |
| BPC-157 | BC202607 | WF03 | 2026-06-26 | Conforms | TrustPointe | View File |
| Tesamorelin | TES202607 | WF03 | 2026-06-26 | Conforms | TrustPointe | View File |
| Semaglutide | SM202607 | VI32 | 2026-06-25 | Conforms | TrustPointe | View File |
| CJC-1295 ND | CJ202606 | WF03 | 2026-06-25 | Conforms | TrustPointe | View File |
| Retatrutide | RT202607 | WF03 | 2026-06-25 | Conforms | TrustPointe | View File |
| Tirzepatide | TZ202605 | WF03 | 2026-06-25 | Conforms | TrustPointe | View File |
| Retatrutide | RTT202606 | WF03 | 2026-06-25 | Conforms | TrustPointe | View File |
| MOTS-c | MC202605 | WF03 | 2026-06-25 | Conforms | TrustPointe | View File |
| PT-141 | PT202605 | VI32 | 2026-06-13 | Conforms | Kovera | View File |
| Retatrutide | RTT202606 | WF03 | 2026-06-12 | Conforms | Kovera | View File |
| Semaglutide | SM202607 | VI32 | 2026-06-11 | Conforms | Kovera | View File |
| Ipamorelin | IP202606 | WF03 | 2026-06-11 | Conforms | Kovera | View File |
| KPV | KV202606 | WF03 | 2026-06-11 | Conforms | Kovera | View File |
| BPC-157 | BC202607 | WF03 | 2026-06-11 | Conforms | Kovera | View File |
| Retatrutide | RT202607 | WF03 | 2026-06-11 | Conforms | Kovera | View File |
| Tirzepatide | TZ202605 | WF03 | 2026-06-10 | Conforms | Kovera | View File |
| Epithalon | ET202604 | WF03 | 2026-05-14 | Conforms | Kovera | View File |
| 5-Amino-1MQ | AM202604 | WF03 | 2026-05-14 | Conforms | Kovera | View File |
| NAD+ | NDB202606 | WF03 | 2026-06-05 | Conforms | TrustPointe | View File |
| Tesamorelin | TES202605 | WF03 | 2026-06-05 | Conforms | TrustPointe | View File |
| Retatrutide | RT202605 | WF03 | 2026-06-05 | Conforms | TrustPointe | View File |
| TB-500 | TB202605 | WF03 | 2026-06-05 | Conforms | TrustPointe | View File |
| GHK-Cu | CU202605 | WF03 | 2026-05-26 | Conforms | TrustPointe | View File |
| CJC-1295 ND / Ipamorelin | CJIP202605 | WF03 | 2026-05-26 | Conforms | TrustPointe | View File |
| Cagrilintide | CG202607 | WF03 | 2026-05-26 | Conforms | TrustPointe | View File |
| SS-31 | SS202602 | WF03 | 2026-05-24 | Conforms | TrustPointe | View File |
| AOD-9604 | AO202605 | WF03 | 2026-05-24 | Conforms | TrustPointe | View File |
| GLOW Blend | GW202603 | WF03 | 2026-05-24 | Conforms | TrustPointe | View File |
| KLOW Blend | KW202602 | WF03 | 2026-05-24 | Conforms | TrustPointe | View File |
| CJC-1295 ND / Ipamorelin | CJIP202605 | WF03 | 2026-05-16 | Conforms | Kovera | View File |
| Cagrilintide | CG202607 | WF03 | 2026-05-16 | Conforms | Kovera | View File |
| CIT: CJC-1295 ND / Ipamorelin / Tesamorelin | CIT202604 | WF03 | 2026-04-26 | Conforms | Kovera | View File |
| Tesamorelin | TES202604 | WF03 | 2026-04-22 | Conforms | Kovera | View File |
| Pinealon | PN202603 | WF03 | 2026-05-05 | Conforms | TrustPointe | View File |
| Semax | SX202603 | WF03 | 2026-05-05 | Conforms | TrustPointe | View File |
| MOTS-c | MC202602 | WF03 | 2026-05-05 | Conforms | TrustPointe | View File |
| Cagrilintide | CG202603 | VI32 | 2026-05-05 | Conforms | TrustPointe | View File |
| SS-31 | SS202601 | WF03 | 2026-05-05 | Conforms | TrustPointe | View File |
| CJC-1295 ND/Ipamorelin | CJIP202602 | WF03 | 2026-05-05 | Conforms | TrustPointe | View File |
| DSIP | DS202605 | WF03 | 2026-04-24 | Conforms | Kovera | View File |
| BPC-157/TB-500 | BB202605 | VI32 | 2026-04-21 | Conforms | Kovera | View File |
| KLOW Blend | KW202604 | WF03 | 2026-04-21 | Conforms | Kovera | View File |
| Retatrutide | RT202604 | WF03 | 2026-04-22 | Conforms | Kovera | View File |
| AOD-9604 | AO202605 | WF03 | 2026-04-20 | Conforms | Kovera | View File |
| SS-31 | SS202601 | WF03 | 2026-04-02 | Conforms | Kovera | View File |
| BPC-157/TB-500 | BB202604 | WF03 | 2026-04-03 | Conforms | TrustPointe | View File |
| Cagrilintide | CG202603 | VI32 | 2026-03-31 | Conforms | Kovera | View File |
| Pinealon | PN202603 | WF03 | 2026-04-01 | Conforms | Kovera | View File |
| GLOW Blend | GW202603 | WF03 | 2026-04-01 | Conforms | Kovera | View File |
| KLOW Blend | KW202602 | WF03 | 2026-04-01 | Conforms | Kovera | View File |
| CJC-1295 ND/Ipamorelin | CJIP202602 | WF03 | 2026-04-01 | Conforms | Kovera | View File |
| SS-31 | SS202602 | WF03 | 2026-04-01 | Conforms | Kovera | View File |
| MOTS-c | MC202602 | WF03 | 2026-04-01 | Conforms | Kovera | View File |
| Tesamorelin | TES202603 | WF03 | 2026-04-03 | Conforms | TrustPointe | View File |
| Sermorelin | SER202601 | VI32 | 2026-03-29 | Conforms | Kovera | View File |
| MOTS-c | MC202603 | VI32 | 2026-04-01 | Conforms | Kovera | View File |
| Retatrutide | RT202603 | WF03 | 2026-04-03 | Conforms | TrustPointe | View File |
| Semax | SX202603 | WF03 | 2026-03-31 | Conforms | Kovera | View File |
| GLOW Blend | GW202603 | WF03 | 2026-03-26 | Conforms | Kovera | View File |
| Tirzepatide | TZ202603 | VI32 | 2026-03-26 | Conforms | Kovera | View File |
| BPC-157 | BC202604 | WF03 | 2026-03-17 | Conforms | Kovera | View File |
| Thymosin Alpha-1 | TA202602 | WF03 | 2026-02-25 | Conforms | Kovera | View File |
| NAD+ | NDB202601 | VI32 | 2026-02-08 | Conforms | Kovera | View File |
| Ipamorelin | IP202601 | WF03 | 2026-01-26 | Conforms | TrustPointe | View File |
| TB500 | TB202601 | WF03 | 2026-01-26 | Conforms | TrustPointe | View File |
| Retatrutide | RT202602 | WF03 | 2026-01-26 | Conforms | TrustPointe | View File |
| Semaglutide | SM202601 | MZ21 | 2026-01-19 | Conforms | TrustPointe | View File |
| Cagrilintide | CAG202601 | MZ21 | 2026-01-19 | Conforms | TrustPointe | View File |
| Tesamorelin | TES202601 | WF03 | 2026-01-19 | Conforms | TrustPointe | View File |
| BPC-157 | BP202512 | WF03 | 2026-01-08 | Conforms | TrustPointe | View File |
| BPC-157/TB-500 | BB202512 | WF03 | 2026-01-08 | Conforms | TrustPointe | View File |
| Tirzepatide | TZ20250915 | DF05 | 2025-12-03 | Conforms | TrustPointe | View File |
| TB500 (TB4) | TB20250614 | SH07 | 2025-11-24 | Conforms | TrustPointe | View File |
| BPC-157 | BP20250808 | WF03 | 2025-11-12 | Conforms | TrustPointe | View File |
| BPC/TB500 | BB20250630 | SH07 | 2025-11-12 | Conforms | TrustPointe | View File |
| CJC-1295 ND | CJ20250724 | WF03 | 2025-11-12 | Conforms | TrustPointe | View File |
| GHK-Cu | CU20250717 | SH07 | 2025-11-12 | Conforms | TrustPointe | View File |
| Ipamorelin | IP20250721 | WF03 | 2025-11-12 | Conforms | TrustPointe | View File |
| Retatrutide | RP20251020 | DF05 | 2025-11-12 | Conforms | TrustPointe | View File |
| Sermorelin | SM20250723 | WF03 | 2025-11-12 | Conforms | TrustPointe | View File |
| SS-31 | SY20250806 | WF03 | 2025-11-12 | Conforms | TrustPointe | View File |
| TB500 (TB4) | TB20250614 | SH07 | 2025-11-12 | Conforms | TrustPointe | View File |
| Tesamorelin | TS20250722 | WF03 | 2025-11-12 | Conforms | TrustPointe | View File |
| Tirzepatide | TZ20250730 | EJ12 | 2025-11-12 | Conforms | TrustPointe | View File |
Current Sterility Certifications
Swipe right to view full table →
| Product | Batch Id | Manufacturer | Date | USP Pass/Fail | Rapid Pass/Fail | Laboratory | File |
|---|---|---|---|---|---|---|---|
| Kisspeptin-10 | KSS2607 | VI32 | 2026-06-30 | Pass | Kovera | View File | |
| Retatrutide | RTT2613 | WF03 | 2026-06-30 | Pass | Kovera | View File | |
| CJC-1295 ND | CJ202606 | WF03 | 2026-06-26 | Pass | TrustPointe | View File | |
| Ipamorelin | IP202606 | WF03 | 2026-06-26 | Pass | TrustPointe | View File | |
| Reconstitution Solution | BAC202603 | VI32 | 2026-06-26 | Pass | TrustPointe | View File | |
| MOTS-c | MC202605 | WF03 | 2026-06-23 | Pass | TrustPointe | View File | |
| NAD+ | NDB202606 | WF03 | 2026-06-15 | Pass | TrustPointe | View File | |
| Tesamorelin | TES202605 | WF03 | 2026-06-15 | Pass | TrustPointe | View File | |
| Retatrutide | RTT202606 | WF03 | 2026-06-12 | Pass | Kovera | View File | |
| PT-141 | PT202605 | VI32 | 2026-06-12 | Pass | Kovera | View File | |
| Semaglutide | SM202607 | VI32 | 2026-06-10 | Pass | Kovera | View File | |
| Ipamorelin | IP202606 | WF03 | 2026-06-10 | Pass | Kovera | View File | |
| KPV | KV202606 | WF03 | 2026-06-10 | Pass | Kovera | View File | |
| BPC-157 | BC202607 | WF03 | 2026-06-10 | Pass | Kovera | View File | |
| Retatrutide | RT202605 | WF03 | 2026-06-12 | Pass | Kovera | View File | |
| CJC-1295 ND | CJ202606 | WF03 | 2026-06-09 | Pass | Kovera | View File | |
| Retatrutide | RT202607 | WF03 | 2026-06-09 | Pass | Kovera | View File | |
| Tirzepatide | TZ202605 | WF03 | 2026-06-09 | Pass | Kovera | View File | |
| Epithalon | ET202604 | WF03 | 2026-05-14 | Pass | Kovera | View File | |
| GHK-Cu | CU202605 | WF03 | 2026-05-29 | Pass | TrustPointe | View File | |
| Epithalon | ET202604 | WF03 | 2026-05-14 | Pass | Kovera | View File | |
| 5-Amino-1MQ | AM202604 | WF03 | 2026-05-14 | Pass | Kovera | View File | |
| Reconstitution Solution | BAC202602 | VI32 | 2026-05-14 | Pass | Kovera | View File | |
| CJC-1295 ND / Ipamorelin | CJIP202605 | WF03 | 2026-05-14 | Pass | Kovera | View File | |
| Cagrilintide | CG202607 | VI32 | 2026-05-14 | Pass | Kovera | View File | |
| CIT: CJC-1295 ND / Ipamorelin / Tesamorelin | CIT202604 | WF03 | 2026-05-07 | Pass | Kovera | View File | |
| DSIP | DS202605 | WF03 | 2026-05-07 | Pass | – | Kovera | View File |
| BPC-157/TB-500 | BB202605 | VI32 | 2026-04-21 | Pass | Kovera | View File | |
| Retatrutide | RT202604 | WF03 | 2026-04-22 | Pass | – | Kovera | View File |
| KLOW Blend | KW202604 | WF03 | 2026-04-21 | – | Pass | Kovera | View File |
| AOD-9604 | AO202605 | WF03 | 2026-04-20 | – | Pass | Kovera | View File |
| Cagrilintide | CG202603 | VI32 | 2026-04-12 | Pass | – | Kovera | View File |
| SS-31 | SS202601 | WF03 | 2026-04-12 | – | Pass | Kovera | View File |
| MOTS-c | MC202603 | VI32 | 2026-04-04 | Pass | – | Kovera | View File |
| Bacteriostatic Water | BAC202601 | WF03 | 2026-01-13 | Pass | – | TrustPointe | View File |
| Bacteriostatic Water | BAC20250807 | SH07 | 2025-09-09 | Pass | – | TrustPointe | View File |
| Meta-Z | MZR20250713 | DF05 | 2025-08-26 | Pass | – | TrustPointe | View File |
Verifiable certificates
When obtaining research peptides, it is essential to validate the authenticity of the Certificate of Analysis (COA). Certificate fraud runs rampant throughout the research peptide supply community. The two most common forms are doctored images and stolen certificates. You can check for these two by making sure the third-party laboratory’s website shows that the certificate belongs to the supplier and the values haven’t been doctored. TrustPointe Analytics provides a few simple rules for verification:
When obtaining research peptides, it is essential to validate the authenticity of the Certificate of Analysis (COA). Certificate fraud runs rampant throughout the research peptide supply community. The two most common forms are doctored images and stolen certificates. You can check for these two by making sure the third-party laboratory’s website shows that the certificate belongs to the supplier and the values haven’t been doctored. TrustPointe Analytics provides a few simple rules for verification:
Beware of fraudulent laboratories
Not only must one remain vigilant about potentially fraudulent certificates, one must also be aware that there are third-party laboratories whose results cannot be considered reliable or scientifically valid. Unfortunately, there is significant evidence to suggest that one of the most popular third-party testing labs does not use scientifically sound methodologies and, in some cases, has fabricated results. There isn’t an easy remedy for this problem, but when labs are particularly bad, there tend to be a lot of discussion threads on various social platforms.
Interpreting Endotoxin Results (via TrustPointe)
Our friends at TrustPointe have provided the following detailed explanation to help interpret the results of the endotoxin testing.
We use the Charles River Endosafe PTS system to test for bacterial endotoxins following USP <85> guidelines:
- USP <85> Bacterial Endotoxin Result: <x.xx EU/mL
Because it’s reported as “<x.xx” this indicates the test did not detect endotoxin above the detection limit of the cartridge. - If a result is above the limit of detection of the cartridge, it will be reported as a number (without the “<“).
The following are suitability parameters that verify the system was working properly and the sample prep dilution is appropriate for accurate results. Peptides often interfere with endotoxin detection due to their tendency to bind or mask endotoxins, which can lead to inaccurate low results. To overcome this, samples are typically tested at a large dilution to reduce matrix interference and ensure reliable recovery and detection in compliance with USP <85>. If the dilution is not correct, the run will fail suitability and we’ll need to adjust the dilution to ensure accurate results. We provide the suitability data to customers for transparency and so they can be confident in the results.
USP <85> Sample CV %:
- CV stands for coefficient of variation, a measure of repeatability.
- For our lab, CV has to be <25% or the result to be considered valid
USP <85> Spike CV %:
- This refers to the precision of the positive control (spiked sample).
- Again, for our lab CV has to be <25% or the result to be considered valid
USP <85> Spike Recovery
- This tells us how much of the known endotoxin spike was recovered from your sample.
- The acceptable range is 50–200% per USP <85>
NOT SUITABLE FOR HUMAN CONSUMPTION – INTENDED FOR RESEARCH ONLY
Thank you for choosing Peptide Partners.
NOTICE: All information provided above is strictly intended for educational and informational purposes. Our products are designed for research use solely and are not approved for human consumption. Please refrain from any form of ingestion.
By making a purchase from Peptide Partners, you acknowledge that you are acquiring Research Chemicals. Our products are exclusively intended for laboratory research purposes.
It is imperative that only qualified and licensed professionals handle this product. Under no circumstances should it be utilized as a drug, agricultural or pesticide product, food additive, or household chemical. Misrepresentation of this product for such purposes is strictly prohibited by law. All content on our website is provided for educational use exclusively. Any form of introduction into the human or animal body is illegal.
Related products
Metabolics
Metabolics
Metabolics
Metabolics
Metabolics
Metabolics
Metabolics